MENLO PARK , Calif.-- ( BW HealthWire ) --May 31 , 2001--Geron Corporation ( Nasdaq : GERN ) announced today that David B. Karpf , M.D. , has joined the company as executive medical director for oncology
We welcome Dr. Karpf into our oncology development group and look forward to his
contributions toward advancing our oncology products to the clinic , said Thomas B. Okarma Ph.D. , M.D. , Geron's president and chief executive officer.In his
new position , Dr. Karpf will lead the clinical and regulatory activities associated with our four oncology programs : Diagnostics , Telomerase Inhibitors , Oncolytic Virus , and Telemerase Vaccine..Dr. Karpf
brings to Geron
extensive experience in clinical product development , including successful interactions with the FDA and international regulatory agencies.Most recently , Dr. Karpf was Vice President , Clinical and Regulatory Affairs at Calydon , Inc. where he was responsible for the development of CV706 and CV787 , replication-selective adenoviruses for the treatment of prostate cancer
.Prior to his tenure at Calydon , Dr. Karpf was Senior Director of Clinical Research at Roche Global Development in Palo Alto and was responsible for clinical development activities in metabolic bone disease
.From 1991 to 1996 , Dr. Karpf was Director of Clinical Research at Merck Research Laboratories in Rahway , N.J. During his time at Merck he designed , monitored , and completed Phase 2 , 3 and 4 clinical trials on Fosamax ( R ) and played a pivotal role in the successful NDA and launch of this product
.His academic experience includes a current appointment as Clinical Associate Professor , Department of Medicine , Stanford University School of Medicine as well as prior faculty appointments in the Department of Medicine , UCSF School of Medicine in San Francisco
is a biopharmaceutical company focusing on developing and commercializing therapeutic and diagnostic products for applications in oncology and regenerative medicine , and research tools for drug discovery.Geron's product development programs are based upon three-patented core technologies : telomerase , human embryonic stem cells and nuclear transfer.
To receive an index and copies of recent press releases , call Geron's News on Demand toll-free fax service , 800/782-3279.Additional information about Geron Corporation
can be obtained at www.geron.com.